In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (12/2010)

Executive Summary

A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.

You may also be interested in...



ZetrOZ LLC

Traditional home treatments for chronic pain, such as topical creams, hot pads, cold packs, prescription drugs and transcutaneous nerve stimulation are plentiful, yet only half of America's chronic pain sufferers report their pain as under control. Consumers may soon have a better option for treating their pain: a wearable ultrasound system that is portable, affordable and easy to use. TheraSonX from ZetrOZ LLC uses low-intensity ultrasound delivered through an iPod-sized applicator to provide continuous therapy for up to six hours while patients are engaged in normal activities.

Zeltiq

Zeltiq was founded to commercialize technology based on research demonstrating that fat cells are more susceptible than other types of cells to extreme cold and can be selectively, painlessly and permanently destroyed in a process known as cryolipolysis. With FDA 510(k) clearance for its CoolSculpting system in hand in early September, Zeltiq hopes to lead the charge into the body contouring aesthetics frontier with a technology that it believes stands apart from emerging laser, radiofrequency and ultrasound systems.

NuVue Therapeutics Inc.

A game-changing, silver-bullet approach for diagnosing and treating soft-tissue cancers could replace traditional biopsy techniques and IV chemotherapy. Or so hopes NuVue Therapeutics Inc., which is developing a suite of products that could allow more precise tissue removal through an ultrasound-guided needle with color monitoring for easy visibility, plus reduce the current high rates of toxicity and morbidity associated with chemotherapy. The company says its technology enables very low-volume/highly concentrated dosing, just 1/200th to 1/500th of the standard dose of systemic chemotherapy.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel